Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) PT at $61.18

Tempus AI, Inc. (NASDAQ:TEM) has been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $61.18.

Several equities research analysts recently commented on the company. TD Cowen reissued a “buy” rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Loop Capital lowered their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. JPMorgan Chase & Co. cut Tempus AI from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th. Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Finally, Bank of America upped their target price on Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd.

Tempus AI Trading Up 6.9 %

Shares of NASDAQ TEM opened at $51.35 on Friday. The business has a 50 day simple moving average of $56.35 and a 200 day simple moving average of $51.39. Tempus AI has a 52 week low of $22.89 and a 52 week high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Transactions at Tempus AI

In related news, COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the transaction, the chief operating officer now directly owns 982,442 shares in the company, valued at approximately $38,914,527.62. This represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David R. Epstein sold 990 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $46.83, for a total value of $46,361.70. Following the completion of the transaction, the director now owns 26,284 shares of the company’s stock, valued at $1,230,879.72. The trade was a 3.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,598,969 shares of company stock worth $317,194,162 over the last three months.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TEM. GF Fund Management CO. LTD. acquired a new position in Tempus AI during the fourth quarter worth $108,000. Voloridge Investment Management LLC acquired a new position in Tempus AI during the fourth quarter worth $11,826,000. Two Sigma Advisers LP bought a new stake in shares of Tempus AI during the fourth quarter worth $625,000. ProShare Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter worth $244,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Tempus AI during the fourth quarter worth $1,034,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.